Physician profile
Katherine Grace Ross
NPI 1861077109
$44,231.04
in general payments reported to CMS, 2019-2025
31 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,963 · 2023: $7,004 · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $6,750 · Food and Beverage: $6,613 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,256.54 |
| Travel and Lodging | $6,750.06 |
| Food and Beverage | $6,612.99 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36,022.45 | 2022-2025 | |
| Medtronic, INC. | $1,469.60 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $898.86 | 2022-2025 | Korlym |
| Dexcom, INC. | $788.62 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Xeris Pharmaceuticals, INC. | $709.96 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $677.26 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $637.84 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $538.31 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $401.02 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $287.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.77 | 2021-2025 | Jardiance |
| Insulet Corporation | $253.93 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $226.22 | 2021-2024 | Lokelma |
| Recordati_rare_diseases_inc. | $189.16 | 2021-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $129.50 | 2022-2024 | Tepezza, Repatha, Prolia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $111.30 | 2021 | |
| Antares Pharma, INC. | $92.82 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Cequr Corporation | $61.52 | 2024-2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $52.92 | 2024 | |
| Baxter Healthcare | $51.12 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Averitas Pharma INC. | $51.07 | 2023-2025 | Qutenza |
| Nevro Corp. | $48.40 | 2024 | Senza |
| Ascendis Pharma Endocrinology INC | $45.95 | 2025 | Yorvipath |
| Lexicon Pharmaceuticals, INC. | $37.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $35.00 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $30.89 | 2025 | |
| Eusa Pharma (US) LLC | $25.03 | 2022 | |
| Lundbeck LLC | $21.63 | 2024 | Rexulti |
| Sequel Med Tech, LLC | $20.75 | 2025 | Twiist |
| Globus Medical, INC. | $18.30 | 2025 | Senza |
| Halozyme INC | $16.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.